This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects

1. Browse more Reports on Pharmaceuticals at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
Hyperphosphatemia - Pipeline Review, H2 2015
By
RnRMarketResearch.com
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Publisher Name : Global Markets Direct
Date: 15-Jul-2015
No. of pages: 82
Single User License: US $2000

2. This report provides comprehensive information on the therapeutic development
for Hyperphosphatemia, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic
development for Hyperphosphatemia and special features on late-stage and
discontinued projects.
The report enhances decision making capabilities and help to create effective
counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class
products.
Hyperphosphatemia - Pipeline Review, H2
2015
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441

3. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Hyperphosphatemia - Pipeline Review, H2
2015
Companies Discussed/Mentioned in this Research :
3SBio Inc., Ardelyx, Inc., Galenica Ltd., Medice Arzneimittel Putter GmbH & Co. KG,
OPKO Health, Inc., Panion & Bf Biotech Inc, Sanofi, Spectrum Pharmaceuticals, Inc.
and Toray Industries, Inc.
Drugs Profile Discussed in this Research :
colestilan chloride, CPAM-11, fermagate, ferric citrate, calcium succinate, JPH-101,
niacinamide, PDX-003, PT-20, RDX-002, sevelamer carbonate, Small Molecule to
Target Phosphate for Hyperphosphatemia, Small Molecules to Inhibit Phosphate
Transport for Hyperphosphatemia In CKD, SPI-014, succharated ferric oxide,
tenapanor hydrochloride, TRK-390, VS-501 and VS-505.

4. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Scope For Hyperphosphatemia - Pipeline Review, H2 2015
• The report provides a snapshot of the global therapeutic landscape of
Hyperphosphatemia
• The report reviews key pipeline products under drug profile section which includes,
product description, MoA and R&D brief, licensing and collaboration details & other
developmental activities
• The report reviews key players involved in the therapeutics development for
Hyperphosphatemia and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Hyperphosphatemia products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-
registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects.
Hyperphosphatemia - Pipeline Review, H2
2015

5. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and
insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading
companies
• Identify and understand important and diverse types of therapeutics
under development for Hyperphosphatemia
• Plan mergers and acquisitions effectively by identifying key players of the
most promising pipeline
• Devise corrective measures for pipeline projects by understanding
Hyperphosphatemia pipeline depth and focus of Indication therapeutics
Hyperphosphatemia - Pipeline Review, H2
2015

6. For more details contact Mr. Ritesh Tiwari : sales@rnrmarketresearch.com / +18883915441
RnRMarkertResearch
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Hyperphosphatemia - Pipeline Review, H2
2015